SIGA Technologies Inc. · NASDAQ:SIGA
SIGA Technologies — Investor Presentation (March 2025)
22 slides from SIGA Technologies's investor presentation, March 2025
Slide 1: Company Overview
Company Overview A Leader in Global Health & Infectious Diseases 1
Slide 2: Forward Looking Statements
Forward Looking Statements 2
Slide 3: Contents
Contents 1 Introduction 2 The Smallpox Threat 3 TPOXX®: A Differentiated Product 4 Financial Summary
Slide 4: SIGA at a Glance
SIGA at a Glance We are dedicated to advancing our strategic initiatives, driving shareholder value, and enhancing national health security as we deliver TPOXX to U.S. and global government agencies and progress our clinical programs. - Diem Nguyen, Chief Executive Officer Who We Are SIGA is a publi
Slide 5: SIGA is a Leader in Global Health Security
SIGA is a Leader in Global Health Security Fully Integrated Infectious Disease Capabilities Foundation for Continued Attractive Growth • Highly profitable, commercial stage pharmaceutical company • Opportunities for TPOXX indication expansions (post-exposure operating within infectious disease and h
Slide 6: Executing on our Strategy for Growth
Executing on our Strategy for Growth COMPETITIVE STRATEGIC KEY TRENDS RESULTING IN ADVANTAGE PRIORITIES Greater awareness of the Government contracting Continue our partnership Strong Financial need for preparedness in and relations with the U.S. Government Performance the event of an outbreak Suppl
Slide 7: Comprehensive Capabilities Provide Strong Foundation
Comprehensive Capabilities Provide Strong Foundation Deep Proven R&D capabilities Government Development Close coordination with government agencies to jointly Long-standing relationships Contracting Expertise develop high-impact therapies with key government agencies Experience Ongoing label expans
Slide 8: Experienced Leadership in Infectious Diseases and Government Relations
Experienced Leadership in Infectious Diseases and Government Relations Diem Nguyen, PhD, MBA Dan Luckshire Chief Executive Officer Chief Financial Officer Larry Miller Dennis Hruby General Counsel Chief Scientific Officer 8
Slide 9: Strong, Durable Financial Performance Over Time
Strong, Durable Financial Performance Over Time SIGA is Well Product Revenues ($mm) Pre-tax Operating Income ($mm) Positioned Financially $127 $131 $133 $85 $89 $84 Achieved record 2024 $116 product revenues $70 $87 through a diverse mix of $43 customers Had $70mm of outstanding orders at 2020 2
Slide 10: The Smallpox Threat
The Smallpox Threat 10
Slide 11: Smallpox: Historic Milestones
Smallpox: Historic Milestones Highly contagious and fatal disease in susceptible population 2017 2018 2022 2024 2024 Canadian researchers U.S. FDA EMA and MHRA (UK) U.S. Bipartisan Commission on Japan’s PDMA approves synthesizes horsepox, approves approve Tecovirimat- Biodefense declares “smallpox a
Slide 12: Smallpox Remains a Significant Threat Today
Smallpox Remains a Significant Threat Today Current geopolitical environment heightens the need for vigilance More than Smallpox can spread The ongoing geopolitical Smallpox globally before issues and advancements continues to 30% The Growing pose a serious global threat. Historic 300M symptoms appe
Slide 13: TPOXX: A Differentiated Product
TPOXX: A Differentiated Product 13
Slide 14: TPOXX at a Glance
TPOXX at a Glance A highly targeted antiviral treatment against orthopoxviruses, including smallpox As the first FDA-approved antiviral treatment for smallpox, TPOXX was among the first therapies delivered to the U.S. SNS under Project BioShield. TPOXX’s was developed in partnership with BARDA, and
Slide 15: TPOXX is a Clinically Differentiated Medical Countermeasure
TPOXX is a Clinically Differentiated Medical Countermeasure Antivirals Vaccines TPOXX ACAM2000® TEMBEXA® IMVANEX/IMVAMUNE/ Tecovirimat SIGA, TEPOXX (plus other replicating (CMX001/brincidofovir) JYNNEOS® (MVA-BN®) (ST-246/tecovirimat) vaccinia vaccine) First FDA-approved drug with FDA-approved d
Slide 16: Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX
Demonstrated Track-Record of >$1B Successful Long-Standing Government Contracts for TPOXX 2011 TPOXX CONTRACT 2018 TPOXX CONTRACT Procurement Duration 2011-2018 2018-current Key Agency Involved U.S. Biomedical Advanced Research U.S. Biomedical Advanced Research and Dev. Authority (BARDA) and Dev. Au
Slide 17: Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications
Advancing TPOXX Regulatory Approvals to Accelerate Growth into New Formulations and Indications TPOXX Franchise is the Foundation for Expansion with over $1bn in Multi-Year Contracts PEP Program Monoclonal Antibodies (mAbs) Pediatric Program (post-exposure prophylaxis) Program Addresses time gap b
Slide 18: TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox
TPOXX PEP Aims to Expand Health Benefits When Exposed to Smallpox Antiviral Post-Exposure Prophylaxis Antiviral Treatment (Developing Label Expansion) (FDA Approved) VACCINE (HEALTH SECURITY GAP) TPOXX INCUBATION (ASYMPTOMATIC STAGE) FEVER RASH DAY 1 DAY 4 DAY 14 DAY 17 DAY 20 INFECTION INFECTIOUS S
Slide 19: Cultivate Partnerships to Expand Global Access
Cultivate Partnerships to Expand Global Access Collaborating with Governments and Other Partners on Heath Security is Best-in-Class Core Competency Strong Long-Standing Common Goal of Global Proven Track Record Partnerships Health Security Public Health Emergency Medical Secured over $1 bn in mu
Slide 20: Financial Summary
Financial Summary 20
Slide 21: Strong Financial Performance
Strong Financial Performance ($ in millions) FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 1 U.S. Government Orders under Current Contracts Product Sales ~$520 mm of TPOXX ordered for SNS over the past 5 years Oral TPOXX $113 $113 $7 $110 $84 ~$21 mm of oral TPOXX ordered by the Department of Defense
Slide 22: Key Takeaways
Key Takeaways Leveraging Expanding Driving Organic Expanding Delivering Robust Infectious Disease Successful Growth Platform with Financial Foundation TPOXX Franchise Initiatives Inorganic Growth Performance Leading health security Proven track record of Multiple organic growth Attractive opportunit
SIGA Technologies — Investor Presentation (March 2025) on 6ix